Hye-Sun Park1, Hyun Chang Kim2, Dongdong Zhang3, Hyungseon Yeom2, Sung-Kil Lim4. 1. Department of Endocrinology, H Plus Yangji Hospital, Seoul, Republic of Korea. 2. Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. 3. Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Republic of Korea. 4. Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. lsk@yuhs.ac.
Abstract
PURPOSE: To clarify the association of circulating irisin with muscle, liver and bone, and to evaluate irisin as a biomarker for sarcopenia in postmenopausal women. METHODS: Quadriceps cross-sectional area (QcCSA), bone mineral density (BMD), liver attenuation (measured in Hounsfield units (HU)) were assessed using quantitative computed tomography in 153 postmenopausal women, mean age of 72.20 ± 5.96 years. Muscle strength and physical performance were evaluated by handgrip test and short physical performance battery, respectively. Serum irisin was measured by an enzyme-linked immunosorbent assay kit. In addition, 147 young women were recruited as a reference group to define cut-off values for sarcopenia. RESULTS: Circulating irisin was positively correlated with QcCSA/body weight (BW) and liver HU even after adjusting for multiple covariates, and the serum level was significantly lower in the sarcopenia group (QcCSA/BW<-2SD of the mean values for young women) than in the presarcopenia (-2SD≤QcCSA/BW<-1SD) or control groups (1SD≤QcCSA/BW<2SD). Logistic regression models showed that the relationship between circulating irisin and prevalence of sarcopenia remained significant after adjusting for confounding factors (per 1.0 ng/mL decrease of irisin, odds-ratio = 1.95, 95% confidence interval 1.33-2.87, p-value = 0.001). CONCLUSIONS: In postmenopausal women, serum irisin may be used as a biomarker for sarcopenia, and we showed the potential for the development of irisin-based early screening and staging tool for sarcopenia.
PURPOSE: To clarify the association of circulating irisin with muscle, liver and bone, and to evaluate irisin as a biomarker for sarcopenia in postmenopausal women. METHODS: Quadriceps cross-sectional area (QcCSA), bone mineral density (BMD), liver attenuation (measured in Hounsfield units (HU)) were assessed using quantitative computed tomography in 153 postmenopausal women, mean age of 72.20 ± 5.96 years. Muscle strength and physical performance were evaluated by handgrip test and short physical performance battery, respectively. Serum irisin was measured by an enzyme-linked immunosorbent assay kit. In addition, 147 young women were recruited as a reference group to define cut-off values for sarcopenia. RESULTS: Circulating irisin was positively correlated with QcCSA/body weight (BW) and liver HU even after adjusting for multiple covariates, and the serum level was significantly lower in the sarcopenia group (QcCSA/BW<-2SD of the mean values for young women) than in the presarcopenia (-2SD≤QcCSA/BW<-1SD) or control groups (1SD≤QcCSA/BW<2SD). Logistic regression models showed that the relationship between circulating irisin and prevalence of sarcopenia remained significant after adjusting for confounding factors (per 1.0 ng/mL decrease of irisin, odds-ratio = 1.95, 95% confidence interval 1.33-2.87, p-value = 0.001). CONCLUSIONS: In postmenopausal women, serum irisin may be used as a biomarker for sarcopenia, and we showed the potential for the development of irisin-based early screening and staging tool for sarcopenia.
Authors: Mark P Jedrychowski; Christiane D Wrann; Joao A Paulo; Kaitlyn K Gerber; John Szpyt; Matthew M Robinson; K Sreekumaran Nair; Steven P Gygi; Bruce M Spiegelman Journal: Cell Metab Date: 2015-08-13 Impact factor: 27.287
Authors: Jian-Jun Liu; Sylvia Liu; Melvin D S Wong; Clara S H Tan; Subramaniam Tavintharan; Chee Fang Sum; Su Chi Lim Journal: J Diabetes Complications Date: 2013-10-04 Impact factor: 2.852
Authors: Hae Yoon Choi; Sungeun Kim; Ji Woo Park; Nam Seok Lee; Soon Young Hwang; Joo Young Huh; Ho Cheol Hong; Hye Jin Yoo; Sei Hyun Baik; Byung-Soo Youn; Christos S Mantzoros; Kyung Mook Choi Journal: J Clin Endocrinol Metab Date: 2014-04-29 Impact factor: 5.958
Authors: Joo Young Huh; Grigorios Panagiotou; Vassilis Mougios; Mary Brinkoetter; Maria T Vamvini; Benjamin E Schneider; Christos S Mantzoros Journal: Metabolism Date: 2012-09-25 Impact factor: 8.694
Authors: José María Moreno-Navarrete; Francisco Ortega; Marta Serrano; Ester Guerra; Gerard Pardo; Francisco Tinahones; Wifredo Ricart; José Manuel Fernández-Real Journal: J Clin Endocrinol Metab Date: 2013-02-22 Impact factor: 5.958
Authors: Jian-Jun Liu; Melvin D S Wong; Wan Ching Toy; Clara S H Tan; Sylvia Liu; Xiao Wei Ng; Subramaniam Tavintharan; Chee Fang Sum; Su Chi Lim Journal: J Diabetes Complications Date: 2013-04-22 Impact factor: 2.852
Authors: Matteo Cesari; Roger A Fielding; Marco Pahor; Bret Goodpaster; Marc Hellerstein; Gabor A van Kan; Stefan D Anker; Seward Rutkove; J Willem Vrijbloed; Maria Isaac; Yves Rolland; Christine M'rini; Mylène Aubertin-Leheudre; Jesse M Cedarbaum; Mauro Zamboni; Cornell C Sieber; Didier Laurent; William J Evans; Ronenn Roubenoff; John E Morley; Bruno Vellas Journal: J Cachexia Sarcopenia Muscle Date: 2012-08-03 Impact factor: 12.910
Authors: Cristina Planella-Farrugia; Ferran Comas; Mònica Sabater-Masdeu; María Moreno; José María Moreno-Navarrete; Oscar Rovira; Wifredo Ricart; José Manuel Fernández-Real Journal: Front Physiol Date: 2019-07-10 Impact factor: 4.566